GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Rosetta Genomics Ltd (OTCPK:ROSGQ) » Definitions » Piotroski F-Score

Rosetta Genomics (Rosetta Genomics) Piotroski F-Score : 0 (As of May. 11, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Rosetta Genomics Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rosetta Genomics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Rosetta Genomics's Piotroski F-Score or its related term are showing as below:


Rosetta Genomics Piotroski F-Score Historical Data

The historical data trend for Rosetta Genomics's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rosetta Genomics Piotroski F-Score Chart

Rosetta Genomics Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 4.00 4.00 3.00 2.00

Rosetta Genomics Quarterly Data
Dec10 Mar11 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 3.00 - 2.00 -

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec16) TTM:Last Year (Dec15) TTM:
Net Income was $-16.23 Mil.
Cash Flow from Operations was $-10.37 Mil.
Revenue was $9.23 Mil.
Gross Profit was $1.80 Mil.
Average Total Assets from the begining of this year (Dec15)
to the end of this year (Dec16) was (22.423 + 11.961) / 2 = $17.192 Mil.
Total Assets at the begining of this year (Dec15) was $22.42 Mil.
Long-Term Debt & Capital Lease Obligation was $3.74 Mil.
Total Current Assets was $9.51 Mil.
Total Current Liabilities was $3.80 Mil.
Net Income was $-17.35 Mil.

Revenue was $8.27 Mil.
Gross Profit was $2.00 Mil.
Average Total Assets from the begining of last year (Dec14)
to the end of last year (Dec15) was (17.278 + 22.423) / 2 = $19.8505 Mil.
Total Assets at the begining of last year (Dec14) was $17.28 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $19.37 Mil.
Total Current Liabilities was $2.80 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rosetta Genomics's current Net Income (TTM) was -16.23. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rosetta Genomics's current Cash Flow from Operations (TTM) was -10.37. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec15)
=-16.233/22.423
=-0.72394416

ROA (Last Year)=Net Income/Total Assets (Dec14)
=-17.345/17.278
=-1.00387776

Rosetta Genomics's return on assets of this year was -0.72394416. Rosetta Genomics's return on assets of last year was -1.00387776. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Rosetta Genomics's current Net Income (TTM) was -16.23. Rosetta Genomics's current Cash Flow from Operations (TTM) was -10.37. ==> -10.37 > -16.23 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec16)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec15 to Dec16
=3.74/17.192
=0.21754304

Gearing (Last Year: Dec15)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec14 to Dec15
=0/19.8505
=0

Rosetta Genomics's gearing of this year was 0.21754304. Rosetta Genomics's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec16)=Total Current Assets/Total Current Liabilities
=9.513/3.804
=2.50078864

Current Ratio (Last Year: Dec15)=Total Current Assets/Total Current Liabilities
=19.37/2.803
=6.91045309

Rosetta Genomics's current ratio of this year was 2.50078864. Rosetta Genomics's current ratio of last year was 6.91045309. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Rosetta Genomics's number of shares in issue this year was 1.743. Rosetta Genomics's number of shares in issue last year was 1.258. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=1.795/9.234
=0.1943903

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=1.996/8.268
=0.24141268

Rosetta Genomics's gross margin of this year was 0.1943903. Rosetta Genomics's gross margin of last year was 0.24141268. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec15)
=9.234/22.423
=0.4118093

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec14)
=8.268/17.278
=0.47852761

Rosetta Genomics's asset turnover of this year was 0.4118093. Rosetta Genomics's asset turnover of last year was 0.47852761. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+0+0+0+0+0
=2

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rosetta Genomics has an F-score of 2. It is a bad or low score, which usually implies poor business operation.

Rosetta Genomics  (OTCPK:ROSGQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Rosetta Genomics Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Rosetta Genomics's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Rosetta Genomics (Rosetta Genomics) Business Description

Traded in Other Exchanges
N/A
Address
10 Plaut Street, Science Park, Rehovot, ISR, 76706
Rosetta Genomics Ltd is an Israel based genomic diagnostics company operating globally. It is focused on research and development on diagnostics and therapeutics in the field of microRNAs. The firm markets and sells four diagnostic tests based on its microRNA technologies namely, RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer, mi-LUNG, mi-KIDNEY which is a microRNA-based kidney tumor classification test for pathology samples and RosettaGx Reveal which is a microRNA-based assay for the diagnosis of indeterminate thyroid fine-needle aspirate samples. Its revenues include Clinical testing revenues and Licensing revenues, of which Clinical testing revenue is maximum. The group generates its revenues mainly from diagnosing patient tissue.
Executives
Sabby Management, Llc 10 percent owner 115 HIDDEN HILLS DR, SPICEWOOD TX 78669
Sabby Healthcare Volatility Master Fund, Ltd. 10 percent owner C/O SABBY MANAGEMENT, LLC, 10 MOUNTAINVIEW ROAD, SUITE 205, UPPER SADDLE RIVER NJ 07458